Controlling type 1 diabetes could be as easy as sending a text, literally

Patients living with type 1 diabetes are constantly tinkering with glucose monitors and insulin pumps. All that Dana Lewis, a health communications professional, has to do is text her pancreas--which actually combines an insulin pump and glucose monitor and connects to her smartphone to cut the hundreds of interactions conventional type 1 diabetes requires to just six a day.

Commanding the pancreas to increase blood glucose on the day of a big speech allow for Lewis to plan her day exactly how she needs. Without the hassle of continuous checking of insulin pumps and glucose monitors, she is able to send texts to her pancreas to control her chronic condition and live a more high-quality life while monitoring her diabetes effortlessly.

“Every five minutes, the system pulls data from the pump, and says 'here's what been happening,' and it pulls data from your continuous glucose monitor, which says, 'here's what your blood sugar is, and this rig,' the physical hardware, processes the data from both devices and run it through the devices and run its through the algorithm and says, based on the trend of your blood sugar, and the newest data point, plus what's happening with insulin, plus your personal settings, your about your sensitivity to insulin, what you want to target, and things like that, and you're predicted to be X," said Lewis.

Read the full story below:

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.